Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 1/20 | 0.62 |
| ▸ | MMP8 | P22894 | 1/20 | 0.62 |
| ▸ | MMP14 | P50281 | 1/20 | 0.62 |
| ▸ | SNCA | P37840 | 17/20 | 0.62 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18040137 | 1.00 | MMP9 (0.62) | MMP9MMP8MMP14SNCAMTNR1A | |
| SCHEMBL18040138 | 1.00 | MMP9 (0.62) | MMP9MMP8MMP14SNCAMTNR1A | |
| SCHEMBL892344 | 0.84 | MMP9 (0.65) | MMP9MMP8MMP14SNCAMTNR1A | |
| SCHEMBL892597 | 0.79 | MMP9 (0.79) | MMP9MMP8MMP14SNCAMTNR1A | |
| SCHEMBL23100743 | 0.78 | SNCA (0.53) | SNCAMTNR1AMTNR1BPTGS2 | |
| SCHEMBL23100745 | 0.78 | SNCA (0.53) | SNCAMTNR1AMTNR1BPTGS2 | |
| SCHEMBL9938676 | 0.77 | SNCA (1.00) | SNCA | |
| SCHEMBL892461 | 0.77 | MMP9 (0.79) | MMP9MMP8MMP14SNCAMTNR1A | |
| SCHEMBL18207221 | 0.76 | MMP9 (0.61) | MMP9MMP8MMP14SNCAMTNR1A | |
| SCHEMBL18601568 | 0.76 | MMP9 (0.61) | MMP9MMP8MMP14SNCAMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083475-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083475-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, MAPT, NLN | MMP9 4393/4885MMP8 4446/4885MMP14 3391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.